Key result
Metabolic and bariatric surgery is linked to ~61% complete T2DM remission in class I obesity.
Why the study?
Patients with class I obesity may require metabolic and bariatric surgery for obesity-associated medical problems, but surgery in this obesity class remains under debate.
Does metabolic and bariatric surgery improve obesity-associated medical problems in patients with class I obesity?
Cohort (n=112)
No
Does metabolic and bariatric surgery improve obesity-associated medical problems in patients with class I obesity?
p-value: p=<0.001
Metabolic and bariatric surgery is safe and highly effective for resolving obesity-associated medical problems like T2DM and hypertension in patients with class I obesity.
Suggests benefit for comorbidity remission in class I obesity; leaves open confirmation via randomized trials.
Background Patients with class I obesity may need metabolic and bariatric surgery (MBS) in the presence of obesity-associated medical problems, but MBS in this class of obesity is under debate. This study aimed to investigate the efficacy and safety of MBS in patients with class I obesity. Methods and materials This study was a historical cohort carried out on 112 patients with class I obesity with body mass index (BMI) of 30–35 kg/m 2 with a 24-month follow-up underwent MBS at Rasoul-e-Akram Hospital. The required data were extracted through the Iran National Obesity Surgery Database. The data required for the study consisted of demographic information such as age, gender, and obesity-associated medical problems like type-2 diabetes mellitus (T2DM), hypertension, obstructive sleep apnea, and dyslipidemia before surgery, 6, 12, and 24 months after surgery. Results Mean age of the patients was 38.10 ± 10.04 years; mean BMI was 32.96 ± 1.35 kg/m 2 and 83.9% (n = 94) of patients were female. Out of 18 patients with T2DM, 11 patients (61.11%) had complete remission and seven patients (38.88%) had partial remission. Obstructive sleep apnea, hypertension, dyslipidemia, and gastroesophageal reflux disease were observed in 18 (16.07%), 23 (20.53%), 43 (38.39%), and 13 patients (11.60%) before surgery and resolved at 24-month follow-up. Post-operative complications during the 24-month follow-up were checked to assess safety and there were no De novo gastroesophageal reflux disease, intolerance, leakage, pulmonary thromboembolism, deep vein thrombosis, incisional hernia, hypoalbuminemia (Albumin < 3.5 g/dl), excessive weight loss (BMI < 18.5 kg/m 2 ) at any time during 24-months follow-ups and mortality. Early complications occurred as splenic injury in one case (0.89%), wound infection in one patient (0.89%), and extra-luminal bleeding in 10 (8.92%) after surgery, without any mortality. Conclusion MBS is safe and effective in class I obesity and can be considered in selected patients with obesity-associated medical problems.
No takes yet. Share an insight, caveat, or question.
Kermansaravi et al. (2024) conducted a cohort in Class I obesity with obesity-associated medical problems (n=112). Metabolic and bariatric surgery was evaluated on Complete remission of type 2 diabetes mellitus at 24 months (p=<0.001). Metabolic and bariatric surgery in patients with class I obesity resulted in complete remission of type 2 diabetes in 61.1% of patients and 100% remission of obstructive sleep apnea, hypertension, and dyslipidemia at 24 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: